New drug combo aims to control lymphoma without chemo side effects
NCT ID NCT04268277
First seen Feb 28, 2026 · Last updated May 12, 2026 · Updated 8 times
Summary
This study tested a chemotherapy-free combination of pembrolizumab and rituximab in 22 people with marginal zone lymphoma (a slow-growing blood cancer). The goal was to see if this approach could control the disease as well as standard chemo but with fewer side effects. The trial was terminated early, so results are limited.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for MARGINAL ZONE LYMPHOMA are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Brüderkrankenhaus St. Josef, Klinik für Hämatologie und Onkologie
Paderborn, 33098, Germany
-
Charité Universitätsmedizin Berlin; Hämatologie - Onkologie - Tumorimmunologie
Berlin, 12200, Germany
-
Gemeinschaftspraxis Dr. med. Johannes Mohm, Dr. med. Gabriele Prange-Krex
Dresden, 01307, Germany
-
Gemeinschaftspraxis für Hämatologie und Onkologie
Münster, 48149, Germany
-
Kliniken Maria Hilf GmbH; Klinik für Hämatologie, Onkologie und Gastroenterologie
Mönchengladbach, 41063, Germany
-
Klinikum Chemnitz gGmbH, Klinik für Innere Medizin III
Chemnitz, 09116, Germany
-
Klinikum Oldenburg AöR, Universitätsklinik für Innere Medizin, Onkologie und Hämatologie
Oldenburg, 26133, Germany
-
Klinikum Passau, II. Medizinische Klinik - Hämatologie, Onkologie und Palliativmedizin
Passau, 94032, Germany
-
Klinikum rechts der Isar der TU München, Klinik und Poliklinik für Innere Medizin III
München, 81675, Germany
-
RoMed Klinikum Rosenheim, Med. Klinik II / OTK
Rosenheim, 83002, Germany
-
Robert-Bosch-Krankenhaus; Hämatologie, Onkologie und Palliativmedizin
Stuttgart, 70376, Germany
-
Universitätsklinikum Ulm; Klinik für Innere Medizin Innere Medizin III
Ulm, Baden-Wurttemberg, 89081, Germany
Conditions
Explore the condition pages connected to this study.